BETAMETHASONE BIOGARAN 2 mg Cpr disp séc Fl/20

Dispersible scored tablet.

Betamethasone.................................................................................................................................................2,00 mg

For a scored dispersible tablet.

Excipients with known effect: aspartame (E951) and lactose.

For the full list of excipients, see section Composition.

Excipients:

Conditions or diseases

Collagenoses-connectivites

Evolving flares of systemic diseases, including: disseminated lupus erythematosus, vasculitis, polymyositis, visceral sarcoidosis.

Dermatological

a-Severe autoimmune bullous dermatoses, in particular pemphigus and bullous pemphigoid.

b-Severe forms of infantile haemangiomas.

c-Certain forms of lichen planus.

d-Certain acute urticarias.

e-Severe forms of neutrophilic dermatoses.

Digestive

a-Evolving flares of haemorrhagic rectocolitis and Crohn's disease.

b-Chronic active autoimmune hepatitis (with or without cirrhosis).

c-Severe acute alcoholic hepatitis, histologically proven.

Endocrine

a-Severe subacute de Quervain thyroiditis.

b-Certain hypercalcaemias.

Hematologic

a-Severe immunological thrombocytopenic purpura.

b-Autoimmune hemolytic anemias.

c-In combination with various chemotherapies in the treatment of malignant lymphoid haemopathies.

Acquired or congenital chronic erythroblastopenias.

Infectious

a-Tuberculous pericarditis and severe forms of tuberculosis threatening the vital prognosis.

b-Pneumopathy due to Pneumocystis carinii with severe hypoxia.

Neoplastic

a-Anti-emetic treatment during antineoplastic chemotherapy.

b-Edematous and inflammatory flare associated with antineoplastic treatments (radiotherapy and chemotherapy).

Nephrological

a-Nephrotic syndrome with minimal glomerular lesions.

b-Nephrotic syndrome of primary focal and segmental hyalinosis.

c-Stage III and IV lupus nephropathy.

d-Intrarenal granulomatous sarcoidosis.

e-Vasculitides with renal involvement.

f-Primary extracapillary glomerulonephritis.

Neurological

a-Myasthenia.

b-Cerebral edema of tumoral cause.

c-Chronic, idiopathic, inflammatory polyradiculoneuritis.

d-Infantile spasms (West syndrome)/Lennox-Gastaut syndrome.

e-Multiple sclerosis relapse, following intravenous corticosteroid therapy.

Ophthalmological

a-Severe anterior and posterior uveitis.

b-Edematous exophthalmos.

c-Certain optic neuropathies, following intravenous corticosteroid therapy (in this indication, oral route as first intention is not recommended).

ENT

a-Certain serous otitis media.

b-Nasosinusal polyposis.

c-Certain acute or chronic sinusitis.

d-Seasonal allergic rhinitis in short courses.

e-Acute stridulous laryngitis (subglottic laryngitis) in children.

Respiratory

a-Persistent asthma, preferably in short courses in case of failure of high-dose inhaled treatment.

b-Asthma exacerbations, in particular severe acute asthma.

c-Chronic obstructive pulmonary disease under assessment of the reversibility of the obstructive syndrome.

d-Progressive sarcoidosis.

e-Diffuse interstitial pulmonary fibroses.

Rheumatological

a-Rheumatoid arthritis and certain polyarthritis.

b-Pseudo polymyalgia rheumatica and Horton's disease.

c-Acute rheumatic fever.

d-Severe and refractory cervicobrachial neuralgia.

Allogeneic organ and hematopoietic stem cell transplantation

a-Prophylaxis or treatment of graft rejection.

b-Prophylaxis or treatment of graft-versus-host disease.

Dosage

Reserved for adults

BETAMETHASONE BIOGARAN is more particularly suited to initial treatments or short-term treatments requiring medium or high doses in adults.

For maintenance treatment, more appropriate dosages exist.

In children, more suitable dosages and pharmaceutical forms exist.

The dosage varies depending on the diagnosis, the severity of the condition, the prognosis, the patient's response and tolerance to treatment.

Initial treatment: from 0,05 mg to 0,2 mg/kg/day (i.e. 0,35 mg to 1,2 mg/kg/day prednisone equivalent). For guidance: 1,5 to 6 tablets in an adult weighing 60 kg.

In severe inflammatory diseases, the dosage ranges from 0,1 to 0,2 mg/kg/day of betamethasone (0,75 mg/kg/day to 1,2 mg/kg/day prednisone equivalent). For guidance: 3 to 6 tablets per day for an adult weighing 60 kg.

Very exceptional situations may require higher doses.

In general

The "loading dose" treatment must be continued until sustained control of the disease. The dose reduction must be slow. Achieving withdrawal is the aim sought. Maintaining a maintenance dose (minimum effective dose) is a compromise that is sometimes necessary.

For prolonged treatment and high doses, the initial doses may be divided into two daily intakes. Subsequently, the daily dose may be administered as a single intake, preferably in the morning during a meal.

Discontinuation of treatment

The pace of withdrawal depends mainly on the duration of treatment, the starting dose and the disease.

The treatment leads to suppression of ACTH and cortisol secretion, sometimes with lasting adrenal insufficiency. On withdrawal, discontinuation must be done gradually, in steps because of the risk of relapse: reduction of 10% every 8 to 15 days on average.

For short courses of less than 10 days, stopping treatment does not require tapering.

During dose tapering (prolonged course): at a dosage of 5 to 7 mg prednisone equivalent, when the underlying disease no longer requires corticosteroid therapy, it is desirable to replace the synthetic corticosteroid with 20 mg/day of hydrocortisone until recovery of corticotropic function.

If corticosteroid therapy must be maintained at a dose below 5 mg of prednisone equivalent per day, a small dose of hydrocortisone may be added to reach a hydrocortisone equivalent of 20 to 30 mg per day. When the patient is only on hydrocortisone, the corticotropic axis can be tested by endocrine tests. These tests alone do not rule out the possibility of adrenal insufficiency occurring during stress.

On hydrocortisone or even after stopping, the patient must be warned of the need to increase the usual dose or resume replacement treatment (for example 100 mg of hydrocortisone intramuscularly every 6 to 8 hours) in case of stress: surgical intervention, trauma, infection.

Method of administration

Oral use.

Anti-inflammatory equivalence (equipotency) for 5 mg of prednisone: 0,75 mg of betamethasone.

The tablets may be swallowed as they are with a little water or dissolved in a little water, preferably during meals.

This medicine is generally contraindicated in the following situations (there is, however, no absolute contraindication for corticosteroid therapy with a vital indication):

• hypersensitivity to the active substance or to any of the excipients mentioned in section Composition ;
• any infectious state except for the specified indications (see section Indications) ;
• certain active viral infections (notably hepatitis, herpes, chickenpox, shingles);
• psychotic states not yet controlled by treatment;
• live vaccines;
• due to the presence of aspartame, this medicine is contraindicated in cases of phenylketonuria.

This medicine is generally not recommended in combination with non-antiarrhythmic medicines giving torsades de pointes (see section Interactions).

Special warnings

• In cases of gastroduodenal ulcer, corticosteroid therapy is not contraindicated if anti-ulcer treatment is associated.
• In the case of a history of ulcer, corticosteroid therapy may be prescribed, with clinical monitoring and, if necessary, after fibroscopy.
• Corticosteroid therapy may promote the occurrence of various infectious complications due notably to bacteria, yeasts and parasites. The occurrence of malignant strongyloidiasis is a major risk.

All subjects coming from an endemic area (tropical, subtropical regions, southern Europe) must have a stool parasitological examination and systematic eradication treatment before corticosteroid therapy.

The evolving signs of an infection may be masked by corticosteroid therapy. Before starting treatment, it is important to rule out any possibility of a visceral focus, in particular tuberculosis, and to monitor during treatment for the appearance of infectious pathologies.

In cases of past tuberculosis, prophylactic anti-tuberculosis treatment is necessary if there are significant radiological sequelae and if it cannot be ensured that a well-conducted treatment of 6 months with rifampicin has been given.

• The use of corticosteroids requires particularly appropriate monitoring, notably in elderly subjects and in cases of ulcerative colitis (risk of perforation), recent intestinal anastomoses, renal insufficiency, hepatic insufficiency, osteoporosis, myasthenia gravis.
• This medicinal product contains lactose. Its use is not recommended in patients with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome (rare hereditary disorders).
• A pheochromocytoma crisis, which may be fatal, has been reported after administration of systemic corticosteroids. Corticosteroids must not be administered to patients in whom a pheochromocytoma is suspected or confirmed until an appropriate benefit/risk assessment has been made.

Precautions for use

• In case of long-term corticosteroid treatment:
  • a diet low in rapidly absorbed sugars and high in protein must be associated, because of the hyperglycaemic effect and protein catabolism with a negative nitrogen balance;
  • sodium and water retention is usual, partly responsible for a possible rise in blood pressure. Sodium intake will be reduced for daily doses above 15 or 20 mg prednisone equivalent and moderated in long-term treatments at low doses;
  • potassium supplementation is justified only for high-dose treatments, prescribed for a long duration, or in case of risk of rhythm disorders or associations with a hypokalaemic treatment;
  • the patient must systematically have an intake of calcium and vitamin D;
  • when corticosteroid therapy is essential, diabetes and arterial hypertension are not contraindications, but the treatment may lead to their imbalance. Their management should be reassessed;
  • patients must avoid contact with subjects who have chickenpox or measles.

Visual disturbances may occur during systemic or local corticotherapy (notably via nasal, inhaled and intraocular routes). In case of blurred vision or onset of any other visual symptom during corticotherapy, an ophthalmological examination is required to look for visual disorders, notably cataract, glaucoma, or a rarer lesion such as central serous chorioretinopathy, described with the administration of corticosteroids by systemic or local route.

Combinations not recommended

+ Medicinal products causing torsades de pointes (astemizole, bepridil, erythromycin IV, halofantrine, pentamidine, sparfloxacin, sultopride, terfenadine, vincamine)

Use substances that do not carry the risk of causing torsades de pointes in cases of hypokalaemia.

+ CYP3A inhibitors

Concomitant administration of CYP3A inhibitors, including products containing cobicistat, is expected to increase the risk of systemic side effects. The combination should be avoided, unless the benefits outweigh the increased risk of systemic side effects of corticosteroids; in this case, patients should be monitored for possible systemic side effects of corticosteroids.

Associations subject to Precautions for use

+ Acetylsalicylic acid by general route and, by extrapolation, other salicylates

Decrease in salicylaemia during treatment with corticoids and risk of salicylate overdose after its discontinuation, due to increased elimination of salicylates by corticoids.

Adjust salicylate doses during the combination and after discontinuation of corticoid treatment.

+ Antiarrhythmics causing torsades de pointes (amiodarone, bretylium, disopyramide, quinidine-like agents, sotalol)

Hypokalaemia is a predisposing factor, as are bradycardia and a pre-existing long QT interval.

Prevent hypokalaemia and correct it if necessary; monitor the QT interval. In case of torsades, do not administer antiarrhythmics (electrical overdrive pacing).

+ Oral anticoagulants

Possible impact of corticotherapy on the metabolism of oral anticoagulants and on that of coagulation factors.

Bleeding risk specific to corticotherapy (digestive mucosa, vascular fragility) at high doses or during prolonged treatment exceeding 10 days.

When the combination is justified, reinforce monitoring: biological check at 8th day, then every 15 days during corticotherapy and after its discontinuation.

+ Other potassium-lowering agents (potassium-depleting diuretics alone or in combination, stimulant laxatives, amphotericin B (IV route))

Increased risk of hypokalaemia through additive effect.

Monitor serum potassium and correct if necessary, especially in cases of digitalis therapy.

+ Digitalis glycosides

Hypokalaemia favouring the toxic effects of digitalis.

Monitor serum potassium, correct if necessary, and possibly ECG.

+ Heparins by parenteral route

Heparin aggravates the haemorrhagic risk specific to corticosteroid therapy (digestive mucosa, vascular fragility) at high doses or in prolonged treatment exceeding 10 days.

The combination must be justified; reinforce monitoring.

+ Enzyme inducers: carbamazepine, phenobarbital, phenytoin, primidone, rifabutin, rifampicin

Decrease in plasma levels and efficacy of corticosteroids through increased hepatic metabolism. The consequences are particularly significant in Addisonian patients and in cases of transplantation.

Clinical and biological monitoring, adjustment of the corticosteroid dosage during the combination and after discontinuation of the enzyme inducer.

+ Insulin, metformin, hypoglycaemic sulfonylureas

Elevation of blood glucose, sometimes with ketosis (decreased glucose tolerance caused by corticosteroids).

Inform the patient and reinforce blood and urine self-monitoring, especially at the start of treatment. Possibly adjust the dosage of the antidiabetic agent during treatment with corticosteroids and after its discontinuation.

+ Isoniazid (described for prednisolone)

Decrease in plasma levels of isoniazid. Proposed mechanism: increased hepatic metabolism of isoniazid and decreased metabolism of glucocorticoids.

Clinical and biological monitoring.

+ Gastrointestinal topics: salts, oxides and hydroxides of magnesium, aluminium and calcium (described for prednisolone, dexamethasone)

Decreased digestive absorption of glucocorticoids.

Take gastrointestinal topicals at a distance from glucocorticoids (more than 2 hours if possible).

Associations to be taken into account

+ Antihypertensives

Decreased antihypertensive effect (sodium and water retention by corticosteroids).

+ Interferon alpha

Risk of inhibition of the action of interferon.

+ Live attenuated vaccines

Risk of generalized disease, possibly fatal. This risk is increased in subjects already immunosuppressed by the underlying disease.

Use an inactivated vaccine where one exists (poliomyelitis).

Pregnancy

In animals, experimentation shows a teratogenic effect that varies according to species.

In humans, transplacental passage occurs. However, epidemiological studies have not detected any malformation risk associated with corticosteroid use during the first trimester.

During chronic diseases requiring treatment throughout pregnancy, a slight intrauterine growth retardation is possible. Neonatal adrenal insufficiency has exceptionally been observed after corticosteroid therapy at high doses.

It is justified to observe a period of clinical (weight, diuresis) and biological monitoring of the newborn.

Consequently, corticosteroids may be prescribed during pregnancy if necessary.

Breast-feeding

In case of treatment at high doses and chronically, breastfeeding is not recommended.

They are mainly to be feared at high doses or during prolonged treatment over several months:

• fluid and electrolyte disorders: hypokalemia, metabolic alkalosis, sodium and water retention, arterial hypertension, congestive heart failure;
• endocrine and metabolic disorders: iatrogenic Cushing's syndrome, inertia of ACTH secretion, adrenocortical atrophy sometimes permanent, decreased glucose tolerance, unmasking of latent diabetes, growth arrest in children, menstrual irregularities;
• musculoskeletal disorders: muscle atrophy preceded by muscle weakness (increased protein catabolism), osteoporosis, pathological fractures in particular vertebral compression fractures, aseptic osteonecrosis of the femoral heads;
• digestive disorders: hiccups, gastroduodenal ulcers, ulceration of the small intestine, perforations and digestive hemorrhage; acute pancreatitis has been reported, especially in children;
• skin disorders: acne, purpura, ecchymosis, hypertrichosis, delayed wound healing and angioedema;
• neuropsychiatric disorders:
  • frequently: euphoria, insomnia, excitation;
  • rarely: manic-like episodes, confusional or confusional-oneiric states, convulsions (systemic or intrathecal route);
  • depressive state on discontinuation of treatment.
• ocular disorders: certain forms of glaucoma and cataract; blurred vision (see also section Warnings and precautions).

Reporting ofs suspected adverse effects

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continuous monitoring of the benefit/risk balance of the medicinal product. Health professionals should report any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Centres for Pharmacovigilance - Website: www.signalement-sante.gouv.fr.

Treatment of acute overdose includes gastric lavage and induction of vomiting, followed by symptomatic treatment if necessary.

Pharmacotherapeutic class: glucocorticoid – systemic use (H. Non-sex hormones), ATC code: H02AB01.

Physiological glucocorticoids (cortisone and hydrocortisone) are essential metabolic hormones. Synthetic corticosteroids, including this specialty, are used mainly for their anti-inflammatory effect. At high doses, they decrease the immune response.

Their metabolic and sodium-retaining effect is less than that of hydrocortisone.

Betamethasone is absorbed in the digestive tract. Protein binding is of the order of 60%.

Betamethasone is metabolized in the liver and eliminated by the kidney. The plasma half-life of betamethasone is of the order of 5 hours. The biological half-life is 36 to 54 hours.

18 months.

Store at a temperature not exceeding 25°C.

No special requirements for disposal.

List I

Marketing authorisation (AMM)

CIP 3400938875416 (Fl/20).

Price:

2,72 euros (Fl/20).

Remb Séc soc at 65% based on the TFR: 2.72 euros (Fl/20).
Collection.